Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium-177 DOTA EB TATE - Molecular Targeting Technologies

Next Previous
Drug Profile

Lutetium-177 DOTA EB TATE - Molecular Targeting Technologies

Alternative Names: 177Lu-DOTA-EB-TATE; 177Lu-EBTATE; 177Lu-DOTA-EB-TATE - Molecular Targeting Technologies; EBTATE; Lutetium-177-DOTA-EB-TATE

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Biomedical Imaging and Bioengineering
  • Developer Molecular Targeting Technologies
  • Class Antineoplastics; Drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Nasopharyngeal cancer; Neuroendocrine tumours; Thyroid cancer

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Neuroendocrine-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV, Injection)
  • 13 Jun 2025 National Institute of Diabetes and Digestive and Kidney Diseases plans a phase I/II trial for Thyroid cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) in June 2025(NCT06991738)
  • 27 Feb 2024 Phase-I clinical trials in Nasopharyngeal cancer in Singapore (IV) prior to February 2024 (Molecular Targeting Technologies pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top